autologous anti-mart-1 f5 t-cell receptor gene-engineered tumor infiltrating lymphocytes
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00509288)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous anti-mart-1 f5 t-cell receptor gene-engineered peripheral blood lymphocytes
- autologous anti-mart-1 f5 t-cell receptor gene-engineered tumor infiltrating lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00706992 | Phase 2 | Jun 1, 2008 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00612222 | Phase 2 | Jan 1, 2008 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00509288 | Phase 2 | Jun 1, 2007 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 3 | 1 | 2007 |
| National Institutes of Health (NIH) | Government | 3 | 0 | 1 | 2007 |
2 organizations
Page 1 / 1